

Tommaso Schirinzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3601175/publications.pdf>

Version: 2024-02-01

93
papers

2,227
citations

236833

25
h-index

276775

41
g-index

95
all docs

95
docs citations

95
times ranked

3310
citing authors

#	ARTICLE	IF	CITATIONS
1	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. <i>Movement Disorders</i> , 2016, 31, 802-813.	2.2	127
2	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. <i>Nature Communications</i> , 2019, 10, 3945.	5.8	127
3	Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function. <i>Frontiers in Neuroanatomy</i> , 2011, 5, 6.	0.9	113
4	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. <i>Frontiers in Neurology</i> , 2019, 10, 148.	1.1	89
5	The Nrf2 induction prevents ferroptosis in Friedreich's Ataxia. <i>Redox Biology</i> , 2021, 38, 101791.	3.9	78
6	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2014, 65, 124-132.	2.1	69
7	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 180-184.	2.2	66
8	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 19-25.	1.1	64
9	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 525-532.	1.2	59
10	Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. <i>Neurological Sciences</i> , 2020, 41, 1373-1375.	0.9	59
11	Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2173.	1.8	58
12	Dystonia as a network disorder: a concept in evolution. <i>Current Opinion in Neurology</i> , 2018, 31, 498-503.	1.8	57
13	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during COVID-19 Lockdown. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 797-802.	0.8	53
14	COVID-19: dealing with a potential risk factor for chronic neurological disorders. <i>Journal of Neurology</i> , 2021, 268, 1171-1178.	1.8	50
15	Centrality of Early Synaptopathy in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 103.	1.1	41
16	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. <i>Neurobiology of Aging</i> , 2020, 90, 119-124.	1.5	41
17	<i>PINK1</i> heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. <i>Movement Disorders</i> , 2014, 29, 41-53.	2.2	40
18	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. <i>Frontiers in Neurology</i> , 2015, 6, 86.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2011, 61, 632-637.	2.0	36
20	Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. <i>Neurobiology of Disease</i> , 2016, 91, 21-36.	2.1	36
21	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. <i>Journal of Neurology</i> , 2015, 262, 2164-2170.	1.8	35
22	Effectiveness of robot-assisted gait training on motor impairments in people with Parkinson's disease: a systematic review and meta-analysis. <i>International Journal of Rehabilitation Research</i> , 2018, 41, 287-296.	0.7	34
23	Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia. <i>Neuropharmacology</i> , 2014, 85, 440-450.	2.0	33
24	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <i>Journal of Neural Transmission</i> , 2018, 125, 673-679.	1.4	31
25	CSF α -synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 203-206.	1.1	30
26	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. <i>Reviews in the Neurosciences</i> , 2020, 31, 723-742.	1.4	30
27	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1621-1625.	1.4	27
28	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	1.4	26
29	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
30	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 8-16.	1.1	25
31	Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. <i>Frontiers in Neuroscience</i> , 2019, 13, 889.	1.4	25
32	Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 113-122.	1.5	25
33	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. <i>Cerebellum</i> , 2018, 17, 489-493.	1.4	24
34	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. <i>Brain and Development</i> , 2018, 40, 433-438.	0.6	23
35	Development of SaraHome: A novel, well-accepted, technology-based assessment tool for patients with ataxia. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 188, 105257.	2.6	21
36	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2016, 28, 23-28.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Natural history of a cohort of <i><sc>ABCD</sc>1</i> variant female carriers. <i>European Journal of Neurology</i> , 2019, 26, 326-332.	1.7	19
38	Aberrant striatal synaptic plasticity in monogenic parkinsonisms. <i>Neuroscience</i> , 2012, 211, 126-135.	1.1	18
39	Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimerâ€™s Disease: From Animal Models to the Human Pathology. <i>Cells</i> , 2019, 8, 1430.	1.8	17
40	A Dual Centre Study of Pain in Parkinsonâ€™s Disease and Its Relationship with Other Non-Motor Symptoms. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1817-1825.	1.5	17
41	Validation of low-cost system for gait assessment in children with ataxia. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 196, 105705.	2.6	17
42	Impaired intracortical transmission in G2019S leucine richâ€repeat kinase Parkinson patients. <i>Movement Disorders</i> , 2017, 32, 750-756.	2.2	16
43	Assessment of serum uric acid as risk factor for tauopathies. <i>Journal of Neural Transmission</i> , 2017, 124, 1105-1108.	1.4	16
44	Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 57-63.	1.1	16
45	Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. <i>Neuroscience</i> , 2011, 177, 240-251.	1.1	15
46	One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2). <i>Cerebellum and Ataxias</i> , 2019, 6, 15.	1.9	15
47	Increase of Prokineticinâ€2 in Serum of Patients with Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1031-1033.	2.2	15
48	Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. <i>Neuropharmacology</i> , 2016, 101, 460-470.	2.0	12
49	The effect of postural deformities on back function and pain in patients with Parkinsonâ€™s disease. <i>NeuroRehabilitation</i> , 2019, 44, 419-424.	0.5	12
50	Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. <i>Cerebellum</i> , 2020, 19, 126-130.	1.4	12
51	Spread of dystonia in patients with idiopathic adultâ€onset laryngeal dystonia. <i>European Journal of Neurology</i> , 2018, 25, 1341-1344.	1.7	11
52	SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 329-332.	0.7	11
53	Amyloid-Î²42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinsonâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1171-1178.	1.2	11
54	Effects of head trauma and sport participation in young-onset Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1185-1193.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings. <i>Clinical Neurology and Neurosurgery</i> , 2017, 156, 63-65.	0.6	10
56	Novel Homozygous KCNJ10 Mutation in a Patient with Non-syndromic Early-Onset Cerebellar Ataxia. <i>Cerebellum</i> , 2018, 17, 499-503.	1.4	10
57	Does Pisa syndrome affect upper limb function in patients with Parkinson's disease? An observational cross-sectional study. <i>NeuroRehabilitation</i> , 2018, 42, 143-148.	0.5	10
58	Non-invasive Focal Mechanical Vibrations Delivered by Wearable Devices: An Open-Label Pilot Study in Childhood Ataxia. <i>Frontiers in Neurology</i> , 2018, 9, 849.	1.1	10
59	The influence of postural deformities on neck function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 79-84.	0.5	10
60	Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson's disease cohort. <i>Npj Parkinson's Disease</i> , 2021, 7, 82.	2.5	10
61	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt-Jakob disease. <i>Journal of the Neurological Sciences</i> , 2015, 348, 274-276.	0.3	9
62	Promising rodent models in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S10-S14.	1.1	9
63	Friedreich ataxia in COVID-19 time: current impact and future possibilities. <i>Cerebellum and Ataxias</i> , 2021, 8, 4.	1.9	8
64	Biofluids profile of \pm -Klotho in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 62-64.	1.1	8
65	Tau and Amyloid- β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. <i>Frontiers in Neurology</i> , 2022, 13, 748599.	1.1	8
66	CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone—a case report. <i>Neurological Sciences</i> , 2014, 35, 1151-1152.	0.9	7
67	Serum uric acid in Friedreich Ataxia. <i>Clinical Biochemistry</i> , 2018, 54, 139-141.	0.8	7
68	Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment. <i>Movement Disorders</i> , 2022, 37, 228-230.	2.2	7
69	Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame. <i>Journal of Clinical Medicine</i> , 2022, 11, 1065.	1.0	7
70	Using a Video Device and a Deep Learning-Based Pose Estimator to Assess Gait Impairment in Neurodegenerative Related Disorders: A Pilot Study. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4642.	1.3	7
71	Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?. <i>Neurological Sciences</i> , 2014, 35, 2013-2015.	0.9	6
72	Longitudinal gait assessment in a stiff person syndrome. <i>International Journal of Rehabilitation Research</i> , 2018, 41, 377-379.	0.7	6

#	ARTICLE	IF	CITATIONS
73	Pisa Syndrome in Parkinson's Disease: Evidence for Bilateral Vestibulospinal Dysfunction. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	6
74	Movement disorders in ADAR1 disease: Insights from a comprehensive cohort. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 100-104.	1.1	6
75	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. <i>Neurological Sciences</i> , 2022, 43, 387-392.	0.9	6
76	Spinal vascular lesions: anatomy, imaging techniques and treatment. <i>European Journal of Radiology Open</i> , 2021, 8, 100369.	0.7	6
77	Double hit mouse model of Parkinson's disease. <i>Oncotarget</i> , 2016, 7, 80109-80110.	0.8	6
78	Clinical course of paroxysmal dyskinesias throughout pregnancy. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 19-20.	1.1	5
79	What substance P might tell us about the prognosis and mechanism of Parkinson's disease?. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 131, 899-911.	2.9	5
80	Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression. , 2017, 07, .		4
81	Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results. <i>Sensors</i> , 2021, 21, 3767.	2.1	4
82	Outlining a Population at Risk of Parkinson's Disease: Evidence from a Case-Control Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	3
83	Long-term treatment with rotigotine in drug-naïve PSP patients. <i>Acta Neurologica Belgica</i> , 2019, 119, 113-116.	0.5	3
84	A wearable video-oculography based evaluation of saccades and respective clinical correlates in patients with early onset ataxia. <i>Journal of Neuroscience Methods</i> , 2020, 338, 108697.	1.3	3
85	Transient MR-angiography changes associated with morphological alterations in epileptic seizure: A short case series. <i>Journal of the Neurological Sciences</i> , 2016, 360, 25-29.	0.3	2
86	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 421-424.	0.8	2
87	Dopaminergic involvement in a drummer with focal dystonia: A case study. <i>Clinical Neurology and Neurosurgery</i> , 2018, 166, 54-55.	0.6	2
88	Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. <i>Neurological Sciences</i> , 2021, 42, 905-910.	0.9	2
89	How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 87-92.	1.2	1
90	Working memory, attention and planning abilities in NKX2.1-related chorea. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 24-27.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Neuroimaging findings in leukoencephalopathy with calcifications and cysts: case report and review of the literature. <i>Neurological Sciences</i> , 2021, 42, 4471-4487.	0.9	1
92	How relevant is the cholinergic system in DYT1 dystonia?. <i>Basal Ganglia</i> , 2012, 2, 227-230.	0.3	0
93	Response to Jardim and colleagues regarding comments on "Natural history of a cohort of <sc>ABCD</sc>1 variant female carriers"™. <i>European Journal of Neurology</i> , 2019, 26, e77.	1.7	0